Post-menopausal osteoporosis: advantages of teriparatide over risedronate sodium

2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...

Read more →

Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept

27 May 2022 - The institute recommends platform studies under a master's protocol. ...

Read more →

G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit

19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...

Read more →

Methods paper: new version 6.1 becomes effective – English translation now available

2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...

Read more →

Supply related data in manufacturer dossiers: things are not going smoothly yet

19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science.  ...

Read more →

Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer

19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...

Read more →

Prospective measures to combat rising drug prices in Germany

13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...

Read more →

Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland

24 March 2022 - Even as prices rose substantially in the U.S. over a recent 12 year period, a new ...

Read more →

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...

Read more →

Criticism of study planning: patient-reported endpoints are often collected far too briefly

3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...

Read more →

Triple negative breast cancer: survival benefit with sacituzumab govitecan

1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...

Read more →

Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus

15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...

Read more →

Register study on gene therapy with Zolgensma starts

1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...

Read more →

Method paper: new version 6.1 comes into force

24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...

Read more →

The G-BA classifies three drugs as reserve antibiotics

20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...

Read more →